ClinicalTrials.gg
RecruitingNCT06574880STARLiTUpdated Nov 18, 2026

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

A Phase 1/2 interventional study of Lu-PSMA-617 and 5-fraction Stereotactic Body Radiation Therapy (SBRT) in Malignant Neoplasm of Prostate and Locally Advanced Prostate Cancer, sponsored by Angela Y. Jia, MD PhD. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Angela Y. Jia, MD PhD · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Nov 18, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms — 21 open to participants now, 31 under way, 2 of them phase 3. lutetium (¹⁷⁷Lu) vipivotide tetraxetan · Prostatic Neoplasms.

Planned enrollment
23rd of 41
45 · median 49
Started
2025
with 7 others
Phase 1/2
8 of 41
2 open now
Primary completion
2027-01
later than 9 of 30 live
Registered
30th of 41
by date
Lead sponsor
1 of 41
Angela Y. Jia, MD PhD

Among the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms, this one is the 23rd largest by planned enrollment, is one of 8 that started in 2025, is one of 8 in phase 1/2, reaches primary completion later than 9 of the 30 other live ones, and was the 30th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

21 of the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About lutetium (¹⁷⁷Lu) vipivotide tetraxetan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to is to investigate if it is possible to lower the chance of cancer reoccurrence and also preserve quality of life by using the drug Pluvicto instead of androgen-deprivation therapy to the usual radiation therapy for advanced local prostate cancer.

Participants will receive one dose of Pluvicto, followed by radiation about 6 weeks later. Radiation therapy will be completed in 5 treatments over the period of 2 weeks. A second dose of Pluvicto will be given 6 weeks after radiation is complete. Some participants may also receive a third dose of Pluvicto, and this would be given 6 weeks after the second dose of Pluvicto.

Read the detailed description

Prostate cancer is the most common cancer in men worldwide and second leading cause of cancer death in men. The most common treatment for prostate cancer is radiation therapy (RT) plus long-term androgen deprivation therapy (ADT) for 18-36 months with a consideration for the addition of abiraterone acetate.

With the introduction of abiraterone and other second generation androgen signaling inhibitors (ARSIs) there is great interest in shortening the duration of systemic therapy. This interest stems from the high toxicity rates of ADT and substantial impact on patient-reported quality of life (QoL). The use of ADT is associated with some adverse events. Therefore, the combination of adverse event risks and decrease in quality of life associated with castration have resulted in decreased compliance to long term ADT and even ARSIs, where approximately 50% of patients with locally advanced disease either decline any ADT or stop treatment early. The goal of this clinical trial is to is to investigate if it is possible to lower the chance of cancer reoccurrence and also preserve quality of life by using the drug Pluvicto instead of androgen-deprivation therapy to the usual radiation therapy for advanced local prostate cancer.

This clinical trial will evaluate the safety of using Lu-PSMA-617 with SBRT to the prostate and pelvic lymph nodes, and to determine whether Lu-PSMA-617 can replace androgen deprivation therapy (ADT) to improve oncologic outcomes by use of cytotoxic agents, avoid ADT related side effects, and improve compliance for participants to receive systemic therapy.

03

Conditions studied

  • Malignant Neoplasm of Prostate
  • Locally Advanced Prostate Cancer

Browse trials for

Keywords

  • Prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 18 years of age.
  • performance status ≤ 1
  • Histologic confirmation of prostate adenocarcinoma of the prostate
  • PSMA avid disease on PSMA PET/CT, where the tumor in the prostate has SUVmax ≥ 10.

    • PSMA PET/CT must be obtained within 4 months.
  • Need ≥ 1 criteria:

    • Node positive disease on PSMA PET/CT or conventional imaging, as defined by having any of the following:

      • Pelvic nodal disease (cN1) as defined by LN stations that commence at the bifurcation of the common iliac vessels
      • Regional nodal disease (M1a) as defined by LN stations that commence at the bifurcation of the aorta and bifurcation of the proximal inferior vena cava to the common iliac veins.
    • In the absence of nodal , must have ≥ 2 of the following

      • i. cT3a or cT3b by conventional imaging (MRI) or PSMA PET/CT
      • ii. Grade group ≥ 4
      • iii. PSA ≥ 40 ng/mL
  • Adequate organ and marrow function to receive treatment:

    • > 10 g/dL
    • White blood cell (WBC) > 3000 / mL
    • ≥ 1,500 / mcL
    • ≥ 100,000 / mcL
    • Creatinine ≤ 1.5x
    • Estimated (eGFR)* > 50 mL/min
    • Total ** \< 2× ULN
    • Albumin > 3 g/dL
    • (AST) \< 3× ULN

      • *based upon Chronic Kidney Disease- Epidemiology Collaboration (CKD-EPI) equation. Participants with estimated GFR between 50 - 60 mL/min will require a 99mTc-TPA GFR test and only participants with non-obstructive pathology will be included in the study.
      • ** Total bilirubin ≤ 2x ULN (except for participants with known Gilbert's Syndrome ≤ 3x ULN is permitted)
  • International Prostate Symptoms Score (IPSS) ≤ 15.
  • Medically fit for treatment and agreeable to follow-up.
  • Ability to understand and the willingness to sign a written .
  • Participants with partners of , agreement to use barrier method (condom) and to continue its use for 14 weeks from receiving the last dose of Lu-PSMA-617. Participants must also not donate sperm for 14 weeks from receiving the last dose of Lu-PSMA-617.

Exclusion criteria

Exclusion Criteria:

  • Clinical or radiographic evidence of distant disease (M1a above aortic bifurcation, M1b, or M1c) by any imaging. Participants are allowed to M1a nodal disease that is below the aortic bifurcation. Negative PSMA PET/CT is an acceptable substitute to conventional staging.
  • Prostate gland size >90 cc measured by CT, ultrasound, or MRI
  • Prior head and neck radiation therapy.
  • Prior treatment for prostate cancer (incudes chemotherapy, radiation therapy, or anti-androgen therapy).
  • Prohibited within 30 days prior to administration to study treatment: spironolactone and other drug therapies.
  • Prohibited 3 months before participant registration and during administration of study treatment: oral ketoconazole, , estrogens, and radiopharmaceuticals.
  • History of prior pelvic radiation therapy.
  • Enrollment concurrently in another investigational drug study within 6 months of registration.
  • History of another active within the previous 3 years except for adequately treated skin cancer or superficial bladder cancer.
  • History of prior myelodysplastic syndrome or acute leukemia.
  • History of or active Crohn's disease or ulcerative colitis.
  • to or inability to tolerate PSMA/PET.
  • Any condition that in the opinion of the investigator would preclude participation in this study.
  • Inability to adhere to radiation safety measures in hospital or at home
  • Prior treatment with radionuclide therapies, 177Lu-PSMA-617 or other
  • Reduced salivary gland function with baseline Gr > 1 dry mouth will be excluded.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Lu-PSMA-617 + SBRT

    * Lu-PSMA-617: 7.4GBq intravenous infusion once with cycle 1, followed by 7.4GBq cycle 2 that is delivered 6 weeks after SBRT , and potentially 7.4GBq cycle #3 delivered 6 weeks after cycle #2 pending dose escalation * Radiation therapy: 5 fractions to prostate and elective nodal irradiation, SBRT, delivered 6 weeks after cycle 1 of 177Lu-PSMA-617

    Drug: Lu-PSMA-617 · Radiation: 5-fraction Stereotactic Body Radiation Therapy (SBRT)

Interventions

  • DrugLutetium (¹⁷⁷Lu) vipivotide tetraxetanStudies of Lutetium (¹⁷⁷Lu) vipivotide tetraxetanLutetium (¹⁷⁷Lu) vipivotide tetraxetan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Lu-PSMA will be administered at a fixed dose of 7.4GBq per cycle, on a dose escalation schedule: * Level 0: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT. * Level 1 (Starting Dose Level): Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2. * Level 2: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2, followed 6 weeks later by cycle 3.

    Also known as: Pluvicto

  • Radiation5-fraction Stereotactic Body Radiation Therapy (SBRT)

    Prostate and nodal SBRT will begin at the completion of cycle 1 (6 weeks after the first Lu-PSMA-617 infusion, ± 4 weeks).

    Also known as: SBRT

06

What researchers measure

Primary outcomes

  1. Phase I: Maximum tolerated dose (MTD) of Lu-PSMA-617

    The Phase I goal is to determine the maximally tolerated dose (MTD) of Lu-PSMA-617 when administered with prostate SBRT treatment. The MTD will be captured by analyzing the incidence of dose limiting toxicities occurring within the four weeks after the last dose of treatment.

    Time frame: 4 weeks after final dose of treatment (treatment expected to last up to six months)

  2. Phase II: Androgen deprivation therapy (ADT)-free survival

    The Phase II goal is to determine the 3-year rate of ADT-free survival.

    Time frame: 3 years post treatment

Secondary outcomes

  1. PSA Progression Free Survival

    PSA progression-free survival will be analyzed at 24 months post last dose of treatment.

    Time frame: 2 years post treatment

  2. Overall Survival (OS)

    Overall Survival (OS) is defined as the time from Day 1 until death due to any cause. For subjects who do not die, time to death will be censored at the time of last contact.

    Time frame: 5 years post treatment

  3. Prostate Cancer-specific Survival (PCSM)

    Prostate cancer specific mortality (PCSM) is defined the time from Day 1 to death directly attributable to prostate cancer, death from treatment complications, or death from unknown causes in participants with active prostate cancer or previously documented clinical or biochemical relapse.

    Time frame: 5 years post treatment

  4. Cumulative incidence of distant metastases

    Distant metastases (DM) is defined as the time from Day 1 until development of distant metastases on CT, MRI, bone scan or PSMA PET, or death from prostate cancer.

    Time frame: 5 years post treatment

  5. Time to any salvage therapy

    The time to any salvage therapy, or Time-to-next-intervention (TTNI), is defined as is defined as the time from Day 1 to the time of initiation of any additional (i.e., outside of planned protocol treatment) cancer-directed therapy, including but not limited to androgen deprivation, other systemic prostate cancer therapeutics, palliative radiotherapy, or surgical intervention specifically addressing complications of metastases. In the absence of a defining event, TTNI will be censored at the date of last visit documenting absence of interventions.

    Time frame: 5 years post treatment

  6. Change in Quality of life score as measured by EPIC-26

    EPIC-26 is a short form version of the full Expanded Prostate Cancer Index Composite (EPIC). This version contains 26 items and the same 5 domains as the full version of EPIC: urinary incontinence, urinary irritative/obstructive, bowel, sexual, and hormonal. Response options for each EPIC item for a Likert scale, and multi-item scare scores are transported linearly to a 0-100 scale with higher scores representing better QoL. The time frame asked in the question relates to symptoms experienced within the prior 4 weeks.

    Time frame: Baseline to 5 years post treatment

  7. Change in Quality of life score as measured by XeQoLS

    Xerostomia-related Quality of Life Questionnaire (XeQoLS) is a questionnaire used to measure how dry mouth and salivary dysfunction affect participants' quality of life (QoL). This questionnaire consists of 15 questions across four major domains: physical functioning, personal/psychological functioning, social functioning, and pain/discomfort issues. The XeQoLS is a self-administered tool, and participants are asked to rate each symptom on a 5-point Likert scale from 0 to 4, with higher scores indicating increased xerostomia burden. An average of scores in each domain is calculated, and the average score ranges from 0 to 4. A total score is calculated as an average of the scores from each of the domain.

    Time frame: Baseline to 5 years post treatment

  8. Change in Quality of life score as measured by FACT-RNT

    FACT-RNT is a patient-reported outcomes (PRO) measure for PCa participants receiving radionuclide therapy. It has not yet been validated in a prospective manner. It consists of 15 questions on a 5-point Likert scale, in a recall period of the past 7 days. Each item score is added, and the sum is linearly transformed to produce the final summary score ranging from 0 to 100, with higher scores representing better QoL.

    Time frame: Baseline to 5 years post treatment

  9. Time-to-castration-resistant prostate cancer

    To determine the average time-to-castration-resistant prostate cancer.

    Time frame: 5 years post treatment

  10. Rate of participants with post treatment PSA in goal range

    Rate of obtaining a post-treatment PSA of ≤ 0.5 ng/mL following treatment with 177Lu-PSMA-617 and prostate and nodal SBRT.

    Time frame: 12 weeks post treatment

  11. Incidence of acute toxicity

    The goal is to describe acute toxicity following treatment with Lu-PSMA-617 and prostate and nodal SBRT.

    Time frame: 5 years post treatment

  12. Incidence of late toxicity

    The goal is to describe late treatment toxicity following treatment with Lu-PSMA-617 and prostate and nodal SBRT.

    Time frame: 5 years post treatment

  13. Biochemical recurrence (BCR)

    To determine the rate of biochemical recurrence (BCR), defined as PSA nadir + 2 ng/mL.

    Time frame: 5 years post treatment

  14. Proportion of participants with PSA50-RR

    The proportion of participants with PSA50-RR at 12 weeks post all treatment will be summarized with 95% confidence interval (CI), where PSA50-RR is defined as the proportion of men with a PSA reduction of at least 50% at 6 weeks after the last 177Lu-PSMA-617 treatment, compared with baseline PSA prior to 177Lu-PSMA-617 treatment.

    Time frame: 12 weeks post treatment

07

Study locations

1 of 1 sites recruiting
  • University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center
    Cleveland, Ohio 44106, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlies publication

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Compiled and analyzed participant data will be published upon study completion. Publisher may request Protocol and Statistical Analysis Plan.

Access criteria: To be shared with investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jan 2027, 19 months after the start.

Of 114 non-industry phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 85. This study's planned 19 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Aug 28, 2024
StartActual
May 13, 2025
Primary completionEst.
Jan 1, 2027was Sep 2026
CompletionEst.
Mar 1, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2026→Jan 1, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Sep 1, 2026→Jan 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06574880
Lead sponsor
Angela Y. Jia, MD PhD
Responsible party
Angela Y. Jia, MD PhD (Principal Investigator, Case Comprehensive Cancer Center) — Sponsor-investigator
First posted
Aug 28, 2024
Start date
May 13, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Angela Y Jia, MD, PhD
Contact
Angela.Jia@UHhospitals.org
216-844-3262
Angela Y Jia, MD, PhD
principal investigator · University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Daniel E Spratt, MD
study chair · University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium (¹⁷⁷Lu) vipivotide tetraxetan

Start the discussion